Heron Theraps Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HERON THERAPS INC, and what generic alternatives to HERON THERAPS INC drugs are available?
HERON THERAPS INC has four approved drugs.
There are thirty-four US patents protecting HERON THERAPS INC drugs.
There are ninety-nine patent family members on HERON THERAPS INC drugs in twenty-one countries and seven supplementary protection certificates in four countries.
Summary for Heron Theraps Inc
International Patents: | 99 |
US Patents: | 34 |
Tradenames: | 4 |
Ingredients: | 3 |
NDAs: | 4 |
Drugs and US Patents for Heron Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-004 | May 12, 2021 | RX | Yes | Yes | 11,083,797 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-001 | May 12, 2021 | DISCN | Yes | No | 9,801,945 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Heron Theraps Inc | ZYNRELEF KIT | bupivacaine; meloxicam | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | 211988-003 | May 12, 2021 | DISCN | Yes | No | 11,844,837 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Heron Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Heron Theraps Inc | SUSTOL | granisetron | INJECTABLE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 10,357,570 | ⤷ Subscribe |
Heron Theraps Inc | SUSTOL | granisetron | INJECTABLE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 9,913,910 | ⤷ Subscribe |
Heron Theraps Inc | SUSTOL | granisetron | INJECTABLE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | 8,252,305 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Heron Theraps Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3134070 | ⤷ Subscribe |
Hong Kong | 1213477 | ⤷ Subscribe |
Spain | 2837149 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Heron Theraps Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0734381 | 04C0010 | France | ⤷ Subscribe | PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111 |
0734381 | PA2004002,C0734381 | Lithuania | ⤷ Subscribe | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
0734381 | SPC/GB04/011 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.